EXACT Sciences (NASDAQ: EXAS) and Senomyx (NASDAQ:SNMX) are both medical companies, but which is the superior business? We will contrast the two companies based on the strength of their risk, dividends, profitability, analyst recommendations, valuation, institutional ownership and earnings.
Valuation and Earnings
This table compares EXACT Sciences and Senomyx’s top-line revenue, earnings per share (EPS) and valuation.
|Gross Revenue||Price/Sales Ratio||Net Income||Earnings Per Share||Price/Earnings Ratio|
|EXACT Sciences||$265.99 million||27.40||-$114.39 million||($0.99)||-60.39|
|Senomyx||$29.32 million||1.98||-$1.26 million||($0.03)||-40.00|
Senomyx has lower revenue, but higher earnings than EXACT Sciences. EXACT Sciences is trading at a lower price-to-earnings ratio than Senomyx, indicating that it is currently the more affordable of the two stocks.
Insider & Institutional Ownership
89.1% of EXACT Sciences shares are held by institutional investors. Comparatively, 30.2% of Senomyx shares are held by institutional investors. 3.2% of EXACT Sciences shares are held by company insiders. Comparatively, 13.0% of Senomyx shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.
This is a breakdown of current recommendations and price targets for EXACT Sciences and Senomyx, as reported by MarketBeat.
|Sell Ratings||Hold Ratings||Buy Ratings||Strong Buy Ratings||Rating Score|
EXACT Sciences presently has a consensus target price of $62.83, indicating a potential upside of 5.09%. Given EXACT Sciences’ higher possible upside, equities research analysts plainly believe EXACT Sciences is more favorable than Senomyx.
This table compares EXACT Sciences and Senomyx’s net margins, return on equity and return on assets.
|Net Margins||Return on Equity||Return on Assets|
Risk and Volatility
EXACT Sciences has a beta of 0.86, meaning that its stock price is 14% less volatile than the S&P 500. Comparatively, Senomyx has a beta of 1.48, meaning that its stock price is 48% more volatile than the S&P 500.
Senomyx beats EXACT Sciences on 7 of the 12 factors compared between the two stocks.
EXACT Sciences Company Profile
Exact Sciences Corporation, a molecular diagnostics company, focuses on developing products for the early detection and prevention of various cancers in the United States. The company offers Cologuard, a non-invasive stool-based DNA screening test for the early detection of colorectal cancer and pre-cancer. It has license agreements with MAYO Foundation for Medical Education and Research; and Hologic, Inc. Exact Sciences Corporation was founded in 1995 and is headquartered in Madison, Wisconsin.
Senomyx Company Profile
Senomyx, Inc. discovers, develops, and commercializes flavor ingredients and natural high intensity sweeteners primarily for the packaged food, beverage, and ingredient supply industries in the United States. The company develops and/or commercializes sweet, savory and salt flavor ingredients, bitter blockers and cooling agents. It sells various flavor ingredients directly to flavor companies. The company has collaboration agreements with Ajinomoto Co., Inc.; Firmenich SA; and PepsiCo, Inc. Senomyx, Inc. was founded in 1998 and is headquartered in San Diego, California.
Receive News & Ratings for EXACT Sciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for EXACT Sciences and related companies with MarketBeat.com's FREE daily email newsletter.